# Binge Eating Liraglutide Intervention

> **NCT03279731** · PHASE3 · TERMINATED · sponsor: **Kelly Allison** · enrollment: 36 (actual)

## Conditions studied

- Binge-Eating Disorder

## Interventions

- **DRUG:** Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03279731
- **Lead sponsor:** Kelly Allison
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-09-29
- **Primary completion:** 2019-09-30
- **Final completion:** 2019-10-01
- **Target enrollment:** 36 (ACTUAL)
- **Why stopped:** The study was not meeting recruitment goals.
- **Last updated:** 2020-11-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03279731

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03279731, "Binge Eating Liraglutide Intervention". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03279731. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*